This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Alysa McCall, director of conservation outreach and staff scientist at Polar Bears International, joined Cheddar to discuss the ongoing fight to protect polar bears from extinction while world leaders gathered to discuss the climate crisis. McCall explained her organization's mission "to ensure the long term survival of polar bears by helping ensure their arctic sea ice habitat remains intact." McCall said she hopes actionable steps are taken after the UN climate summit to mitigate the crisis and not just more promises.
Moderna reported a massive miss on revenue in its Q3 earnings, taking in $5 billion versus the expected $6.21 billion despite sales of the COVID-19 vaccine. The pharmaceutical giant's stock dropped sharply on the news.
Carlo and Baker discuss the fallout from Tuesday's election and the flashing warning sign for Dems ahead of the midterms. Also, a big 2A case at the Supreme Court, Aaron Rodgers has Covid and is in big trouble, and a first for the MCU.
Carlo and Baker discuss the election results across the country, including a Republican comeback in Virginia -- and possibly NJ -- plus the CDC gives the go-ahead for child vaccinations, Atlanta wins the World Series and more.
Dr. Julie Morita, executive vice president of Robert Wood Johnson Foundation, joined Cheddar to discuss the CDC advisory panel recommending the Pfizer vaccine for children ages 5-11. "We've seen many millions of children getting sick, many hospitalized, many dying because of COVID," Morita said. "And so now we have a new tool that we can use to keep our children safe." She also noted that hesitancy among parents about vaccinating their children will likely fade in time as the childhood vaccine program gets underway.
Matthew Oxenford, Analyst at the Economist Intelligence Unit, joins a special edition of Cheddar Climate, where he discusses the responsibilities big businesses across multiple sectors have when it comes to combating the effects of climate change around the world.
President Joe Biden introduced the Global Methane Pledge on the second day of the United Nations climate summit. The U.S. and the European Union will lead the way when it comes to methane emissions reductions, and close to 100 nations have also signed on. It's seen as the fastest way to slow down global warming and keep nations on track toward meeting the goal of keeping warming just 1.5 degrees Celsius above late 1800s atmospheric levels. Dr. Sweta Chakraborty, U.S. President of climate-focused startup 'We Don't Have Time' joins Cheddar Climate to discuss the importance of the Biden administration's methane regulations -- and the importance of U.S. leadership when it comes to climate issues.
John Paul Mejia, the national spokesperson for the Sunrise Movement, joined Cheddar to talk about what the youth activist group wants to see from President Joe Biden as he attends the COP26 climate summit. Mejia admonished the president for having little to deliver on his own climate agenda domestically while at the conference. "We need the president to follow through with his promises because, frankly, it's a matter of life or death not only for communities here in the United States but also those looking to us around the world," he said.
With COP26 kicking off, roughly 120 world leaders and delegates are in Glasgow, Scotland to hold climate talks this week. As experts continue to warn about the dangers of climate change, ESG investing is more important than ever.
Georges Archibald, Head of Apex Americas at Apex Group joined Cheddar's Opening Bell to discuss.
Roughly 20,000 heads of state, diplomats, and activists will gather in person starting Oct. 31 to address the threat of climate change. The summit, known as COP26, is seen as a crucial step in getting the crisis under control as scientists warn global warming is only getting worse. Carroll Muffett, President and CEO of the Center for International Environmental Law, joined Cheddar to explain the goals of COP26 and why it's so crucial for the world leaders to step up and make new, aggressive climate commitments.
